Plain-English translation of NCT03556228 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This clinical trial is testing a new oral medication called VMD-928 to treat advanced cancers—particularly head and neck, lung, esophageal, pancreatic, and mesothelioma cancers—that have high levels of a protein called TrkA. The study will test this medication both by itself and in combination with pembrolizumab, an immunotherapy drug that helps your immune system fight cancer. Researchers want to find the right dose and understand how well and safely this treatment works.
Many advanced cancers stop responding to standard treatments, and patients need new options. This medication is designed to target the TrkA protein that drives certain cancers, offering hope for patients whose tumors have this specific feature and who have run out of other treatment choices.
You likely qualify if…
You likely don't qualify if…
You will visit the research center regularly for check-ups, blood tests, and possibly imaging scans to monitor your health and how the cancer responds to treatment. You will take the medication by mouth as a tablet according to a schedule set by the research team; some participants will take it alone, while others will also receive pembrolizumab infusions every 3 weeks. The study has different phases, starting with finding the right safe dose, then expanding to test that dose in more patients—your involvement will likely span several months with frequent monitoring to ensure your safety.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States